Charles Miller, MD PhD
EyeBiotech Ltd.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charles Miller, MD PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07205887 · A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVOEyeBiotech Ltd. · recruiting · Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) · study director
- Ph2/Ph3NCT06957080 · A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEEyeBiotech Ltd. · active not recruiting · Diabetic Macular Edema (DME) · study director
- Ph2/Ph3NCT06571045 · A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEEyeBiotech Ltd. · active not recruiting · Diabetic Macular Edema (DME) · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.